Patients with moderate SLE who do not have renal involvement represent a distinct clinical group requiring a targeted treatment strategy. This protocol covers that specific presentation and outlines the structured approach to reaching disease control.
This protocol applies to patients with moderate-to-severe arthritis, skin rash covering 9–18% of body surface area, platelet counts of 20–50 × 10&sup9;/L, and serositis — in the absence of renal involvement. Disease activity falls in the SLEDAI 7–12 range, with at least two BILAG B manifestations.
Antimalarial therapy forms the backbone of management for this presentation. Corticosteroids — including short intravenous pulses where needed — may be incorporated based on clinical severity, with the aim of tapering to the lowest effective dose. Additional treatment options are available when the initial approach does not bring the patient to target; the complete sequence and selection criteria are detailed in the full protocol.
The primary aim is full remission (SLEDAI score of 0). Where remission cannot be achieved, a low disease activity state (SLEDAI ≤4) is the accepted secondary target.
DOI: 10.1136/ard-2023-224762
Moderate disease: moderate–severe arthritis (‘RA-like’; rash 9%–18% BSA; PLTs 20–50×10&sup9;/L; serositis; SLEDAI 7–12; ≥2 BILAG B manifestations).
Hydroxychloroquine is recommended for all patients (1b/A), unless contraindicated, at a target dose of 5 mg/kg real body weight/day (2b/B), but individualised based on risk for flare (2b/B) and retinal toxicity.
Glucocorticoids, if needed, are dosed based on the type and severity of organ involvement (2b/C), and should be reduced to maintenance dose of ≤5 mg/day (prednisone equivalent) (2a/B) and, when possible, withdrawn; in patients with moderate-to-severe disease, pulses of intravenous methylprednisolone (125–1000 mg per day, for 1–3 days) (3b/C) can be considered.
Early SLE diagnosis (including serological assessment), regular screening for organ involvement (especially nephritis), prompt initiation of treatment aiming at remission (or low disease activity if this is not possible) and strict adherence to treatment are essential to prevent flares and organ damage, improve prognosis and enhance quality of life.
View source ↗